JP2015524422A5 - - Google Patents

Download PDF

Info

Publication number
JP2015524422A5
JP2015524422A5 JP2015523550A JP2015523550A JP2015524422A5 JP 2015524422 A5 JP2015524422 A5 JP 2015524422A5 JP 2015523550 A JP2015523550 A JP 2015523550A JP 2015523550 A JP2015523550 A JP 2015523550A JP 2015524422 A5 JP2015524422 A5 JP 2015524422A5
Authority
JP
Japan
Prior art keywords
seq
set forth
polypeptide
sequence set
respect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015523550A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015524422A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/065669 external-priority patent/WO2014016362A1/en
Publication of JP2015524422A publication Critical patent/JP2015524422A/ja
Publication of JP2015524422A5 publication Critical patent/JP2015524422A5/ja
Pending legal-status Critical Current

Links

JP2015523550A 2012-07-24 2013-07-24 ワクチン組成物 Pending JP2015524422A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12305908 2012-07-24
EP12305908.1 2012-07-24
EP12305911 2012-07-25
EP12305911.5 2012-07-25
PCT/EP2013/065669 WO2014016362A1 (en) 2012-07-24 2013-07-24 Vaccine compositions for prevention against dengue virus infection

Publications (2)

Publication Number Publication Date
JP2015524422A JP2015524422A (ja) 2015-08-24
JP2015524422A5 true JP2015524422A5 (https=) 2016-09-08

Family

ID=48856641

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015523550A Pending JP2015524422A (ja) 2012-07-24 2013-07-24 ワクチン組成物

Country Status (15)

Country Link
US (1) US20150265695A1 (https=)
EP (1) EP2877207A1 (https=)
JP (1) JP2015524422A (https=)
KR (1) KR20150036593A (https=)
CN (1) CN104812408A (https=)
AU (1) AU2013295016A1 (https=)
BR (1) BR112015001313A2 (https=)
CA (1) CA2878599A1 (https=)
GT (1) GT201500005A (https=)
HK (1) HK1212905A1 (https=)
MX (1) MX2015000446A (https=)
PE (1) PE20150356A1 (https=)
PH (1) PH12014502875A1 (https=)
SG (1) SG11201500439RA (https=)
WO (1) WO2014016362A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20231581T1 (hr) 2013-03-15 2024-03-15 Takeda Vaccines, Inc. Pripravci i postupci za kimerne konstrukte virusa denga groznice u cjepivima
BR112015031226A2 (pt) 2013-06-21 2017-08-29 Merck Sharp & Dohme Composição de vacina, e, uso da composição de vacina
TWI852899B (zh) * 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
KR102532832B1 (ko) * 2014-09-11 2023-05-16 브이엘피 테라퓨틱스 인코포레이티드 플라비바이러스 바이러스 유사 입자
EP3236997B1 (en) * 2014-12-22 2024-05-29 Merck Sharp & Dohme LLC Dengue virus vaccine compositions and methods of use thereof
BR112017028212A2 (pt) 2015-07-03 2018-09-11 Sanofi Pasteur vacinação concomitante contra dengue e febre amarela
WO2017023839A1 (en) 2015-08-03 2017-02-09 The United States Of America As Represented By The Secretary Of The Navy Immune enhancing recombinant dengue protein
FI3355915T3 (fi) * 2015-09-29 2024-01-12 Boehringer Ingelheim Animal Health Usa Inc Koirien parvoviruksen (CPV) viruksen kaltaisten hiukkasten (VLP) rokotteet ja niiden käytöt
WO2018208741A1 (en) 2017-05-08 2018-11-15 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Methods and compositions for the detection of flavivirus infections
SG11202002933TA (en) 2017-10-05 2020-04-29 Sanofi Pasteur Compositions for booster vaccination against dengu
US11576962B2 (en) 2017-12-21 2023-02-14 Green Biomed, Inc. Cross-immunizing antigen vaccine and method for preparation thereof
US11464815B2 (en) * 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
WO2020051334A1 (en) 2018-09-05 2020-03-12 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
SG11202112328TA (en) * 2019-05-15 2021-12-30 Codagenix Inc Attenuated yellow fever virus and uses thereof for the treatment of cancer
CN120271718A (zh) * 2024-01-05 2025-07-08 北京昌平实验室 针对寨卡/登革病毒的重组抗原、其疫苗组合物及其应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
FR2649013B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
FR2649012B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Emulsions multiphasiques injectables
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6254873B1 (en) 1995-04-17 2001-07-03 The United States Of America As Represented By The Secretary Of The Army Inactivated dengue virus vaccine
AU6093296A (en) 1995-06-07 1996-12-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Infectious dengue 2 virus pdk-53 as quadravalent vaccine
HU228705B1 (en) 1997-02-28 2013-05-28 Univ St Louis Chimeric flavivirus vaccines
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
ES2298316T3 (es) 1997-09-05 2008-05-16 Glaxosmithkline Biologicals S.A. Emulsiones de aceite en agua que contienen saponinas.
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
AU4179200A (en) 1999-03-26 2000-10-16 Walter Reed Army Institute Of Research Attenuated dengue-1 virus vaccine
JP2002540166A (ja) 1999-03-26 2002-11-26 ウォルター リード アーミー インスティテュート オブ リサーチ 弱毒化デング熱３型ウイルスワクチン
US6537557B1 (en) 1999-03-26 2003-03-25 The United States Of America As Represented By The Secretary Of The Army Attenuated dengue-4 virus vaccine
US6511667B1 (en) 1999-03-26 2003-01-28 The United States Of America As Represented By The Secretary Of The Army Attenuated dengue-2 virus vaccine
JP2003506039A (ja) * 1999-08-02 2003-02-18 ワイス ｃＤＮＡからの流行性耳下腺炎ウイルスのレスキュー
EP3000477A1 (en) 2000-02-16 2016-03-30 The Government of The United States of America, as represented by the Secretary, Department of Health and Human Services, Avirulent, immunogenic flavivirus chimeras
ATE412738T1 (de) 2000-05-30 2008-11-15 Univ Mahidol Attenuierte stammen von denguevirus und ihre verwendungen in impfstoffzusammensetzungen
AT410634B (de) 2001-02-21 2003-06-25 Franz X Dr Heinz Attenuierte lebendimpfstoffe
KR20040004642A (ko) 2001-05-23 2004-01-13 덴드레온 샌 디에고 엘엘씨 세포 표면 프로테아제에 의해 활성화되는 접합체 및 이의치료학적 용도
WO2002102828A2 (en) 2001-06-01 2002-12-27 Acambis, Inc. Chimeric flavivirus vectors
WO2003010197A2 (en) 2001-07-25 2003-02-06 Genset S.A. Gmg-1 polynucleotides and polypeptides and uses thereof
ATE481982T1 (de) * 2002-05-03 2010-10-15 Us Gov Health & Human Serv Dengue-vakzine mit einer gemeinsamen 30 nukleotid-deletion im 3'-utr der dengue-typen 1 und 2.
US20040259224A1 (en) 2002-05-31 2004-12-23 Farshad Guirakhoo Tetravalent Dengue vaccines
CA2539325C (en) * 2003-09-17 2016-03-22 Duke University Consensus/ancestral immunogens
CN101238144B (zh) 2005-06-17 2012-09-05 赛诺菲巴斯德有限公司 登革血清型1减毒株
BRPI0613287A2 (pt) * 2005-06-17 2010-12-28 Sanofi Pasteur cepa do vìrus da dengue-2 vivo atenuada, composição imunogênica, composição de vacina, ácido nucléico isolado, poliproteìna isolada codificadas pela seq id n .1 ou fragmentos desta e fragmento da poliproteìna
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
US20080193477A1 (en) 2005-08-10 2008-08-14 Acambis Inc. Vaccination Against Dengue Virus Infection
CU23586A1 (es) * 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
US7968102B2 (en) * 2006-01-13 2011-06-28 Sanofi Pasteur S.A. Dengue chimeric viruses
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
FR2903605A1 (fr) 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
CA2676775A1 (en) * 2007-01-31 2008-09-25 Sanofi Pasteur Biologics Co. Flavivirus vaccine vector against influenza virus
US8715689B2 (en) * 2008-04-30 2014-05-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Chimeric west nile/dengue viruses
EP2143440A1 (fr) 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
CA2769645A1 (en) * 2009-07-29 2011-02-03 Bernd Helmut Adam Rehm Polymer particles and uses thereof
US8900596B2 (en) * 2009-11-18 2014-12-02 The Board Of Regents Of The University Of Texas System Physicochemical (PCP) based consensus sequences and uses thereof
GB201007531D0 (en) 2010-05-05 2010-06-23 Imp Innovations Ltd Composition
MX2012012681A (es) * 2010-05-21 2012-12-17 Univ Pittsburgh Secuencias del virus de dengue universales y metodos de uso.
WO2012051491A1 (en) * 2010-10-14 2012-04-19 The United States Of America, As Represented By The Secretary National Institutes Of Health Compositions and methods for controlling neurotropic viral pathogenesis by micro-rna targeting
MX381497B (es) * 2012-07-24 2025-03-12 Sanofi Pasteur Composiciones vacuna.

Similar Documents

Publication Publication Date Title
JP2015524422A5 (https=)
CY1124202T1 (el) Εμβολια ανασυνδυασμενου zika
JP2014502156A5 (https=)
WO2014018858A3 (en) Multimeric fusion protein vaccine and immunotherapeutic
EP3199545A3 (en) Computationally optimized broadly reactive antigens for h1n1 influenza
JP2014000092A5 (https=)
WO2012106377A3 (en) Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
JP2017526689A5 (https=)
JP2013517773A5 (https=)
JP2015524421A5 (https=)
NZ630869A (en) Compositions and methods for dengue virus chimeric constructs in vaccines
JP2015533841A5 (https=)
JP2014534202A5 (https=)
JP2014530010A5 (https=)
JP2011530309A5 (https=)
RU2015135890A (ru) Композиция вакцины
SG10201903538YA (en) Modified virus-like particles of cmv
RU2015138530A (ru) Комбинированная вакцина против респираторно-синцитиального вируса и вируса гриппа
MY170659A (en) Nucleic acid molecules encoding hepatitis b virus core protein and surface antigen protein and vaccine comprising the same
PH12015500499A1 (en) Recombinant measles virus expressing chikungunya virus polypeptides and their applications
CL2012000447A1 (es) Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica.
HK1203524A1 (en) Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses
MX343830B (es) Molecula de acido nucleico que codifica la proteina nuclear del virus de la hepatitis b y vacuna que comprende la misma.
JP2018531624A5 (https=)
JP2014507146A5 (https=)